Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase NA 1

Status

Completed 5Terminated 1

Sponsor Class

NIH 12OTHER 6NETWORK 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 128Lymphoma 107Lymphoma, Large B-Cell, Diffuse 96Leukemia 55Burkitt Lymphoma 50Lymphoma, Non-Hodgkin 49Lymphoma, Follicular 37Lymphoma, Mantle-Cell 33Hodgkin Disease 25Retinoblastoma 16Recurrence 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, T-Cell, Peripheral 16Lymphoma, Large-Cell, Anaplastic 16Central Nervous System Neoplasms 16Neuroblastoma 15Lymphoma, Large-Cell, Immunoblastic 15Lymphoma, B-Cell 15Sarcoma 13Rhabdomyosarcoma 12Lymphoma, B-Cell, Marginal Zone 12Neoplasms 11Medulloblastoma 11Immunoblastic Lymphadenopathy 11Sarcoma, Ewing 10Lymphoma, T-Cell 10Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Biphenotypic, Acute 8Dendritic Cell Sarcoma, Interdigitating 8Enteropathy-Associated T-Cell Lymphoma 7

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 241Melphalan 191Calcium Dobesilate 165fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44Etoposide 39isatuximab 38Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Vincristine × Clear all
NCT00054158 2022-10-03

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Roswell Park Cancer Institute

Phase 2 Completed
24 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00083551 2015-11-23

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

University of Arkansas

Phase 3 Completed
668 enrolled 7 charts
Plasma cell

Multiple Myeloma, Neoplasms

NCT00201695 2015-06-10

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
12 enrolled
Plasma cell

Multiple Myeloma

NCT00577096 2015-04-06

Effects of Exercise in Combination With Epoetin Alfa

University of Arkansas

Phase NA Completed
120 enrolled 16 charts
Plasma cell

Motor Activity, Multiple Myeloma

NCT00215943 2014-04-17

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

H. Lee Moffitt Cancer Center and Research Institute

Phase 3 Terminated
90 enrolled 10 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT01070862 2010-02-18

MAG 2002

University Hospital, Caen

Phase 3 Completed
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡